冠心病患者白细胞miR-223-3p水平与氯吡格雷治疗后的血小板反应无关

目的：探讨冠心病患者白细胞miR-223-3p水平与氯吡格雷治疗后血小板反应之间的潜在相关性。方法：收 集188名择期经皮冠状动脉介入治疗(percutaneous coronary intervention，PCI)术后接受双重抗血小板治疗的门诊患者的 一般资料和血标本，检测二磷酸腺苷(adenosine diphosphate，ADP)诱导的全血血小板聚集率。选取血小板反应有显著 差异的患者(超反应组和无反应组)，检测其白细胞miR-223-3p水平。结果：除ADP诱导的全血血小板聚集率外，两组 患者的一般资料和白细胞miR-223-3p水平差异无统计学意义(P>0.05)。结论：冠心病择期PCI术后门诊患者外周血白细 胞miR-223-3p水平与氯吡格雷治疗后的血小板反应无关。

Leukocyte miR-223-3p is not associated with altered platelet responses to clopidogrel in patients with coronary artery disease

Objective: To investigate the potential correlation between miR-223 level in leukocytes and platelet responses to clopidogrel in patients with coronary artery disease. Methods: A cohort of 188 outpatients, who conducted percutaneous coronary intervention (PCI) and received dual antiplatelet therapy, were recruited. The patient’s electronic health data were collected, and their blood samples were obtained for measurement of adenosine diphosphate (ADP)-induced whole-blood platelet aggregation. Extreme cases of platelet responses to clopidogrel (ultra- vs. non-responder) were measured with miR-223-3p levels in leukocytes. Results: Both groups had similar miR-223-3p levels in leukocytes. There were no significant diff erences in other demographic and clinical data except for metrics of ADP-induced whole-blood platelet aggregation between the 2 group. Conclusion: MiR-223-3p in peripheral leukocytes is not associated with the altered platelet responses to clopidogrel in PCI outpatients.